

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3512174

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
MONDOBIOTECH LABORATORIES AG		12/20/2014
RECEIVING PARTY DATA		
Name:	THERAMETRICS DISCOVERY AG	
Street Address:	DORFPLATZ 6	
City:	STANS	
State/Country:	SWITZERLAND	
Postal Code:	6370	
PROPERTY NUMBERS Total: 8		
Property Type	Number	
Patent Number:	8349805	
Patent Number:	8541364	
Patent Number:	8211856	
Patent Number:	8338380	
Patent Number:	8193149	
Application Number:	12677582	
Application Number:	12677449	
Application Number:	12677472	
CORRESPONDENCE DATA		
Fax Number:	(214)745-5390	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	(214) 745-5356	
Email:	lgopalakrishnan@winstead.com	
Correspondent Name:	WINSTEAD PC	
Address Line 1:	P.O. BOX 131851	
Address Line 4:	DALLAS, TEXAS 75313	
ATTORNEY DOCKET NUMBER:	47012-G99999	
NAME OF SUBMITTER:	LEKHA GOPALAKRISHNAN	
SIGNATURE:	/Lekha Gopalakrishnan/	

DATE SIGNED:	09/03/2015
--------------	------------

Total Attachments: 14

source=Mondo_TherapeuticsAssgn#page1.tif
source=Mondo_TherapeuticsAssgn#page2.tif
source=Mondo_TherapeuticsAssgn#page3.tif
source=Mondo_TherapeuticsAssgn#page4.tif
source=Mondo_TherapeuticsAssgn#page5.tif
source=Mondo_TherapeuticsAssgn#page6.tif
source=Mondo_TherapeuticsAssgn#page7.tif
source=Mondo_TherapeuticsAssgn#page8.tif
source=Mondo_TherapeuticsAssgn#page9.tif
source=Mondo_TherapeuticsAssgn#page10.tif
source=Mondo_TherapeuticsAssgn#page11.tif
source=Mondo_TherapeuticsAssgn#page12.tif
source=Mondo_TherapeuticsAssgn#page13.tif
source=Mondo_TherapeuticsAssgn#page14.tif

mondoBIOTECH holding AG (SIX:RARE) announces the results of its Annual General Meeting and the election of the Board of Directors.

Stans, Switzerland, 20 June 2013 – mondoBIOTECH holding AG (SIX: RARE) announces that at today's Annual General Meeting, the shareholders have approved all agenda items as proposed by the Board of Directors with large majority of the represented votes. Furthermore, the new Board of Directors has constituted itself and has appointed Dr Raffaele Petrone as Chairman.

The agenda of the Annual General Meeting covered the following items:

1) Annual report and the group financial statements 2012 - 2) Carrying forward of the accumulated loss - 3) Granting of discharge to the members of the Board of Directors and the Group Executive Committee members for their tenures in the business year 2012 – 4) Ordinary Capital Increase – 5) Creation of new Authorized Capital – 6) Change of Company name – 7) Extension of Company's purpose – 8) Re-elections to the Board of Directors of Robert Edward Patterson, Michael A. Keller and Ruggero Gramatica for a further one-year term of office and election to the Board of Directors of Dr. Raffaele Petrone and Filippo Celio for a one-year term of office – 9) election of Ernst & Young Basel as new auditors.

Dr Ruggero Gramatica, CEO of mondoBIOTECH holding AG, commented: "This shareholder's meeting marks the beginning of a new and exciting era for this company. With the almost unanimous approval of the capital increase the shareholders paved the way for the envisaged business combination with Pierrel Research International AG. The Boards of Directors and the management teams of the two companies are convinced that this business combination will allow us to evolve the new combined entity into a tech-based contract research and development organization with the capacity to shape a new paradigm in pharma research and development. The new corporate name THERAMetrics marks the formal beginning of this new era."

AGM results in detail

At today's Annual General Meeting, 34.02 % of the existing shares and 53.75 % of the votes with voting rights were represented.

Annual Report, Financial Statements and Carry-Forward of Loss

The shareholders approved the annual report and the group financial statements for 2012 and agreed to carry forward the loss for the year 2012.

Discharge to the Board of Directors and the Group Executive Committee

The shareholders granted discharge to the members of the Board of Directors and the Group Executive Committee members for the business year 2012.

Ordinary Capital Increase

The shareholders approved with a vast majority the ordinary share capital increase of up to CHF 3'217'865.46 as proposed by the Board of Directors. The proposal received 95.83 % of the votes cast. With the approval of the increase of the ordinary share capital the shareholders supported the envisaged business combination with Pierrel International Research AG. Post business combination, Pierrel S.p.A. and Fin Posillipo S.p.A., the shareholders of Pierrel Research International AG, will together hold approximately 77.3% of the share capital of the new combined entity.

Authorized Capital

The shareholders also approved the creation of an authorized share capital with a vast majority of 95.57 % of the votes cast. This allows the Board of Directors to increase the share capital by a maximum amount of CHF 1'200'000 and to issue up to 120'000'000 shares at any time until 19 June 2015, among others for the purpose of an easier access to the capital market and for responding to strategic business opportunities.

Change of Company name and Extension of Company's purpose

The shareholders approved the change of the company's name into THERAMetrics holding AG as proposed by the Board of Directors. The proposal received a broad support of the votes cast.

Furthermore, the shareholders approved the extension of the company's statutory purpose as proposed by the Board of Directors with 95.94 % of the votes cast.

Elections of the Board of Directors

The shareholders have approved with large majority the re-election of Mr. Robert Edward Patterson, Prof. Michael Alan Keller, Mr. Ruggero Gramatica all members of the Board of Directors, who stood for re-election, for a one-year mandate and furthermore elected with overwhelming majority Mr. Raffaele Petrone and Mr. Filippo Celio as new members of the Board of Directors for a one-year term.

Election of Auditors

In addition, the shareholders elected Ernst & Young, Basel, as new statutory auditors of the company.

Immediately after the Annual Shareholders' Meeting, the newly elected Board of Directors of mondoBIOTECH constituted itself. Thereby, Raffaele Petrone, the CEO of Pierrel S.p.A. and through Fin Posillipo S.p.A. an important investor in Pierrel Research International AG, was appointed as Chairman and Michael Alan Keller as Vice-Chairman of the Board of Directors.

Furthermore, the following directors have been appointed as members of the following committees:

- Audit and Finance Committee: Robert Patterson and Filippo Celio
- Nomination and Compensation Committee: Michael Alan Keller and Raffaele Petrone
- Scientific Committee: Michael Alan Keller and Ruggero Gramatica.

The company is continuing to actively pursuing license and collaborations on its existing pipeline ready for being licensed, currently composed of 8 Medicinal Product Candidates, and actively seeking for additional funds and / or corporate transaction.

About mondoBIOTECH holding AG

mondoBIOTECH holding AG (SIX Swiss Exchange ticker symbol: RARE), an independent Swiss biotech company, discovers drugs for patients suffering from rare diseases through its internally developed Search&Match methodology. In Search&Match mondoBIOTECH's scientists combine their unique knowledge of biologically active human peptides with advanced technology solutions delivering medicinal product candidates for rare diseases to licensing partners.

For further information please contact

mondoBIOTECH holding AG

Andreas Hildenbrand, Lemongrass Communications

Tel.: +41 44 202 5268

andreas.hildenbrand@lemongrass-communications.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning mondoBIOTECH holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of mondoBIOTECH holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. mondoBIOTECH holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

KAUFVERTRAG
PURCHASE AGREEMENT

zwischen / between

THERAMetrics laboratories AG

eine Aktiengesellschaft nach liechtensteinischem Recht mit registriertem Sitz in Vaduz (Liechtenstein), mit der Firmennummer FL-0002.073.023-0, rechtsgültig vertreten durch Peter Schierscher, Mitglied des Verwaltungsrates und Michael Kranz, Mitglied des Verwaltungsrates,

- nachfolgend "**Verkäuferin**" genannt -

a share corporation according to the laws of Liechtenstein, having its registered seat at Vaduz (Liechtenstein), with company number FL-0002.073.023-0, duly represented by Peter Schierscher, member of the board of directors and Michael Kranz, member of the board of directors,

- hereinafter referred to as "**Seller**" -

und / and

THERAMetrics Discovery AG

eine Aktiengesellschaft nach schweizerischem Recht mit registriertem Sitz in Stans (Schweiz), mit der Firmennummer CHE-109.392.445, rechtsgültig vertreten durch Raffaele Petrone, Präsident des Verwaltungsrates, und Franco Merckling, Mitglied des Verwaltungsrates,

- nachfolgend "**Käuferin**" genannt -

a share corporation according to the laws of Switzerland, having its registered seat at Stans (Switzerland), with company number CHE-109.392.445, duly represented by Raffaele Petrone, chairman of the board of directors, and Franco Merckling, Member of the board of directors,

- hereinafter referred to as "**Purchaser**" -

betreffend / concerning

Verkauf/Kauf von Patenten
Sale/Purchase of patents





PATENT

REEL: 036540 FRAME: 0279

PRÄAMBEL / PREAMBULE

- Die Verkäuferin und die Käuferin (zusammen die „Parteien“) gehören der THERAMetrics-Gruppe an (die „THERAMetrics Gruppe“). Die Parteien sind Schwestergesellschaften und 100%-ige Tochtergesellschaften der THERAMetrics holding AG, mit Sitz in Stans, welche an der Schweizer Börse kotiert ist;
- Die Käuferin bezweckt den Erwerb von Immaterialgüterrechten im Bereich der medizinischen Diagnostik und Therapie und deren Verwertung;
- Im Rahmen der Reorganisation der THERAMetrics Gruppe beabsichtigt die Verkäuferin gewisse Patente auf die Käuferin zu übertragen und die Käuferin beabsichtigt gewisse Patente zu übernehmen gemäss den folgenden Vertragsbestimmungen.
- *The Seller and the Purchaser (collectively the "Parties") belong to the THERAMetrics Group of companies (the "THERAMetrics Group"). The parties are co-subsiaries of THERAMetrics holding AG, having its registered seat in Stans and holding 100% of the share capital of both companies. THERAMetrics holding AG is listed on the Swiss stock exchange;*
- *The purpose of the Purchaser is acquisition of intellectual property rights pertaining to medical diagnostics and therapy as well as their exploitation;*
- *As part of the reorganization of the THERAMetrics Group, the Seller desires to sell and transfer to the Purchaser certain patents and the Purchaser desires to buy and accept certain patents, all upon the terms and conditions set forth below.*

Gestützt darauf vereinbaren die Parteien was folgt:

Now, therefore, the Parties agree as follows:

1. KAUFGEGENSTAND / OBJECT

Die Verkäuferin verkauft und überträgt an die Käuferin mit Wirkung per Stichtag gemäss den in diesem Kaufvertrag festgelegten Bestimmungen die folgenden in Annex 1 aufgelisteten Immaterialgüterrechte (der „Kaufgegenstand“). Die Käuferin kauft und übernimmt den Kaufgegenstand per Stichtag mit sämtlichen Rechten zu Eigentum.

With effect as of the Effective Date and in accordance with the regulations of this agreement, the Seller herewith sells and transfers to the Purchaser the following intellectual property rights listed in Annex 1 (the "Object"). The Purchaser buys and accepts the transfer of the Trademark[s] with full right and title as of the Effective Date.

**PATENT****REEL: 036540 FRAME: 0280**

2. KAUFPREIS / PURCHASE PRICE

Der Kaufpreis für den Kaufgegenstand gemäss Ziff. 1 dieses Vertrages ist der Buchwert des Kaufgegenstandes per 31. Dezember 2013 und beträgt CHF 79'409. Der Kaufpreis versteht sich exklusive MwSt.

Die Verkäuferin gewährt der Käuferin im Umfang des Kaufpreises ein Darlehen.

The purchase price for the Object according to Section 1 of the present agreement is the book value of the Object as per 31 December 2013 and amounts to CHF 79'409. The purchase price is quoted excluding VAT.

The Seller grants a loan to the Purchaser in the amount of the purchase price.

3. ANMELDUNGEN/REGISTRIERUNGEN / NOTIFICATIONS/REGISTRATIONS

Die Parteien verpflichten sich sämtliche Anmeldungen und Registrierungen vorzunehmen, sowie sämtliche Unterschriften zu leisten und Unterlagen zu unterzeichnen, die für die Übertragung des Kaufgegenstandes notwendig sind, und sie verpflichten sich sämtliche Rechtshandlungen vorzunehmen im Zusammenhang mit der Übertragung des Kaufgegenstandes.

The Parties agree to provide for any and all necessary notifications and registrations and to sign any and all documents which are necessary in order to effectuate the transfer of the Object as set forth herein, and agree to perform all acts that are necessary or useful in connection with the transfer of the Object.

4. STICHTAG / EFFECTIVE DATE

Ab dem 10. Dezember 2014 ("Stichtag") soll die Käuferin Eigentümerin sämtlicher im Zusammenhang mit dem Kaufgegenstand erworbenen Rechte sein, unabhängig davon ob die nach dem für die Übertragung des Kaufgegenstands anwendbaren Recht notwendigen rechtlichen Schritte vorgenommen worden sind. Der gesamte Nutzen sowie sämtliche Pflichten im Zusammenhang mit dem Kaufgegenstand sind ab dem Stichtag zugunsten bzw. zulasten der Käuferin.

From and after 10 December 2014 ("Effective Date"), the Purchaser shall have sole beneficial rights and title with regard to the Object, regardless of whether all requirements under applicable laws with respect to the transfer of the legal ownership of the Object have been fulfilled. Any and all benefits and obligations in connection with the Object shall be for the account of the Purchaser from and after the Effective Date.



PATENT

REEL: 036540 FRAME: 0281

5. GEWÄHRLEISTUNG/ZUSICHERUNGEN / REPRESENTATIONS/WARRANTIES

Die Verkäuferin gewährleistet, dass vor und zum Zeitpunkt des Wirksamwerdens der Übertragung des Kaufgegenstands:

- a) die Verkäuferin die Inhaberin des Kaufgegenstands ist;
- b) die Verkäuferin berechtigt ist, den Kaufgegenstand zu übertragen und diesen Vertrag abzuschliessen;
- c) keine andere Partei Forderungen auf Übertragung des Kaufgegenstands hat;
- d) der Kaufgegenstand frei von Sicherheiten und Belastungen besteht und nicht durch Sicherheiten und Gebrauchsrechte belastet ist.

Eine weitergehende Gewährleistung, insbesondere für den Wert des Kaufgegenstands wird nicht übernommen.

The Seller represents and warrants to the Purchaser that immediately prior to and upon the transfer of the Object by the Seller to the Purchaser:

- a) The Seller is beneficially entitled to the Object;*
- b) The Seller is fully authorized to transfer the Object and to enter into this Agreement;*
- c) No other party than the Purchaser has any right to claim the transfer of the Object;*
- d) The Object is free of all liens and charges and not encumbered by any security or beneficial right; and*

No further representation or warranties, especially with regard to the value of the Object will be granted.

6. ALLGEMEINE BESTIMMUNGEN / MISCELLANEOUS

Jede Vertragspartei trägt die ihr im Zusammenhang mit dem vorliegenden Vertrag entstehenden Kosten.

Each party bears the costs they have incurred in connection with this agreement.

Änderungen und Ergänzungen dieses Vertrages bedürfen zu ihrer Wirksamkeit der Schriftform.

Any amendments or additions to this agreement shall be valid only if made in writing.

Sollten einzelne Bestimmungen dieses Vertrages unwirksam sein oder werden, so wird dadurch die Gültigkeit der übrigen Vertragsbestimmungen nicht berührt. Die wegfallende Bestimmung ist durch eine Regelung zu ersetzen, die dem wirtschaftlichen Zweck der


**PATENT****REEL: 036540 FRAME: 0282**

weggefallenen Bestimmungen am nächsten kommt. Entsprechendes gilt für den Fall einer Lücke.

The invalidity of any clause or part thereof of this agreement shall cause such clause or part to fall away but will not affect the validity of the remainder of this agreement. By mutual agreement, invalid clauses are to be replaced by provisions which come as close as possible to a successful commercial outcome. The same shall apply mutatis mutandis with regard to the filling of any loopholes.

Dieser Vertrag untersteht schweizerischem Recht. Die Parteien vereinbaren als ausschliesslichen Gerichtsstand Stans.

This agreement shall be construed and enforced in accordance with and shall be governed by the laws of Switzerland. The parties agree to submit any disputes in connection with this agreement to the exclusive jurisdiction of the courts of Stans.

Handwritten signatures and initials in the bottom right corner of the page. There are three distinct marks: a large 'R' or 'P' on the left, a signature 'M.' in the middle, and a signature 'Z.' on the right.

Vodice, D. 12.14

Place, date

Für die Verkäuferin

For the Seller


THERAMetrics laboratories AG



Peter Schierscher

Mitglied des Verwaltungsrats /

Member of the Board of Directors



Michael Kranz

Mitglied des Verwaltungsrats /

Member of the Board of Directors

St. Gallen 20.12.2014


Ort, Datum

Place, date

Für die Käuferin

For the Purchaser


THERAMetrics Discovery AG



Raffaele Petrone

Präsident des Verwaltungsrats /


Chairman of the Board of Directors



Franco Merckling

Mitglied des Verwaltungsrats /

Member of the Board of Directors



PATENT

REEL: 036540 FRAME: 0285

ANNEX 1

Immateriälgüterrechte (Patente) („Kaufgegenstand“)
Intellectual Property Rights (Patents) („Object“)

Internat l Patent Family No	Indications	Drug	Countries granted / in- tention to grant	Official patent Number
1410	All	Aviptadil (+BNP, +BQ-123)	France	EP 1 855 661 B1
1410	All	Aviptadil (+BNP, +BQ-123)	Great Britain	EP 1 855 661 B1
1410	All	Aviptadil (+BNP, +BQ-123)	Germany	EP 1 855 661 B1
1410	All	Aviptadil (+BNP, +BQ-123)	Switzerland	EP 1 855 661 B1
1410	All	Aviptadil (+BNP, +BQ-123)	Italy	EP 1 855 661 B1
1410	All	Aviptadil (+BNP, +BQ-123)	Turkey	EP 1 855 661 B1
1410	All	Aviptadil (+BNP, +BQ-123)	Spain	EP 1 855 661 B1
1410	All	Aviptadil (+BNP, +BQ-123)	Netherlands	EP 1 855 661 B1
1410	All	Aviptadil (+BNP, +BQ-123)	Belgium	EP 1 855 661 B1
1410	All	Aviptadil (+BNP, +BQ-123)	Sweden	EP 1 855 661 B1
1410	All	Aviptadil (+BNP, +BQ-123)	Denmark	EP 1 855 661 B1
1410	All	Aviptadil (+BNP, +BQ-123)	Ireland	EP 1 855 661 B1
1410	All	Aviptadil (+BNP, +BQ-123)	Austria	EP 1 855 661 B1
1410	All	Aviptadil (+BNP, +BQ-123)	USA	US 8,178,489
1410	All	Aviptadil (+BNP, +BQ-123)	China	CN101247794
1410	All	Aviptadil (+BNP, +BQ-123)	India	IN1363 / MUMNP / 2007
1410	All	Aviptadil (+BNP, +BQ-123)	Mexico	MX/a/2007/01093 0
1410	All	Aviptadil (+BNP, +BQ-123)	Australia	AU2006222233
1509	Sarcoidosis	Aviptadil	USA	US 7,951,778

PATENT

REEL: 036540 FRAME: 0286

1510	Pulmonary Arterial Hypertension	Aviptadil, PACAP	USA	US 8,153,599
1512	Idiopathic Pulmonary Fibrosis	Interferon gamma	Europe	EP1455813
2595	Mycobacterium Tuberculosis infections	Gonadorelin (+ Anti-inflamm. peptide 1)	USA	US 8,349,805
2595	Mycobacterium Tuberculosis infections	Gonadorelin	Europe	EP2187921
2595	Mycobacterium Tuberculosis infections	Gonadorelin	Japan	5385279
2591	Mycobacterium Tuberculosis infections	Proadrenomedullin (1-20)	Japan	5385277
2603	Mycobacterium Tuberculosis infections	Leu-Valorphin-Arg (+ AF12198)	Great Britain	EP 2 197 477 B1
2603	Mycobacterium Tuberculosis infections	Leu-Valorphin-Arg (+ AF12198)	Switzerland	EP 2 197 477 B1
2603	Mycobacterium Tuberculosis infections	Leu-Valorphin-Arg	Japan	5395793
2610	Mycobacterium Tuberculosis infections	Octreotide	France	EP 2 188 016 B1
2610	Mycobacterium Tuberculosis infections	Octreotide	Great Britain	EP 2 188 016 B1
2610	Mycobacterium Tuberculosis infections	Octreotide	Switzerland	EP 2 188 016 B1
2610	Mycobacterium Tuberculosis infections	Octreotide	USA	US 8,541,364
2610	Mycobacterium Tuberculosis infections	Octreotide	Japan	5385280
2612	TB, and Hepatitis B Virus infections	Acetalin-2	France	EP 2 187 913 B1
2612	TB, and Hepatitis B Virus infections	Acetalin-2	Great Britain	EP 2 187 913 B1

2612	TB, and Hepatitis B Virus infections	Acetalin-2	Switzerland	EP 2 187 913 B1
2612	TB, General	Acetalin-2	USA	US 8,338,380
2612	Mycobacterium Tuberculosis infections	Acetalin-2	Japan	5385281
2625	Hepatitis B Virus infections	Peptide YY (+ Glucagon-like peptide)	USA	US 8,193,149
2625	Hepatitis B Virus infections	Peptide YY	Japan	5385278
		Peptide YY	USA	
2637	Hepatitis B Virus infections	Urocortin (+ CRF)	France	EP 2 187 940 B1
2637	Hepatitis B Virus infections	Urocortin (+ CRF)	Great Britain	EP 2 187 940 B1
2637	Hepatitis B Virus infections	Urocortin (+ CRF)	Germany	EP 2 187 940 B1
2637	Hepatitis B Virus infections	Urocortin (+ CRF)	Switzerland	EP 2 187 940 B1
2637	Hepatitis B Virus infections	Urocortin	Japan	5385283
2663	Angiogenesis	Neuropeptide EI (+ ACTH 7-38)	France	EP 2 187 901 B1
2663	Angiogenesis	Neuropeptide EI (+ ACTH 7-38)	Great Britain	EP 2 187 901 B1
2663	Angiogenesis	Neuropeptide EI (+ ACTH 7-38)	Switzerland	EP 2 187 901 B1
2663	Angiogenesis	Neuropeptide EI	Japan	5385276
2670	Angiogenesis	Renin inhibitor	France	EP 2 187 915 B1
2670	Angiogenesis	Renin inhibitor	Great Britain	EP 2 187 915 B1
2670	Angiogenesis	Renin inhibitor	Japan	5384501
2677	Angiogenesis	Pro-Ser-Hyp... (+ alpha Endorphin)	Japan	5385282
2683	Angiogenesis	Exorphin C	Japan	5385284
2685	Angiogenesis	Astressin (+ Beta Endorphin)	Japan	5395792
2692	Angiogenesis	Stresscopin-related peptide	Japan	548140
2692	Angiogenesis	Stresscopin-related peptide	France	EP 2 190 447 B1

2692	Angiogenesis	Stresscopin-related peptide	Great Britain	EP 2 190 447 B1
2692	Angiogenesis	Stresscopin-related peptide	Switzerland	EP 2 190 447 B1
2703	Angiogenesis	Galanin	Japan	5395794
2744	Chronic Beryllium Disease	alpha Melanotropin	France	EP 2 187 954 B1
2744	Chronic Beryllium Disease	alpha Melanotropin	Great Britain	EP 2 187 954 B1
2744	Chronic Beryllium Disease	alpha Melanotropin	Switzerland	EP 2 187 954 B1
		alpha Melanotropin	USA	
2754	Angiogenesis	Defensin HNP2	Japan	5491396
2829	Hepatitis B Virus infections	Somatostatin-14 (+IGF-1 1-3)	France	EP 2 190 535 B1
2829	Hepatitis B Virus infections	Somatostatin-14 (+IGF-1 1-3)	Great Britain	EP 2 190 535 B1
2829	Hepatitis B Virus infections	Somatostatin-14 (+IGF-1 1-3)	Switzerland	EP 2 190 535 B1
2829	Hepatitis B Virus infections	Somatostatin-14	USA	US 8,211,856
2829	Hepatitis B Virus infections	Somatostatin-14	Japan	5384502

Handwritten signature

Handwritten number 2

PATENT